Remove Biopharma Remove Competition Remove Networking Remove Specialization
article thumbnail

Enabling the next wave of innovative drug therapies with speciality enzymes

Pharmaceutical Technology

For cell and gene therapy applications, you need a variety of speciality enzymes of the highest purity, specificity, and consistency. Developing best-in-class speciality enzymes. That is a key competitive advantage,” says Laursen. “We The impact could be huge for the biopharma industry.

article thumbnail

Five IDNs to watch in 2023

Clarivate

In a fiercely competitive U.S. healthcare provision landscape, integrated delivery networks, or IDNs, are differentiating their offerings by adding outpatient treatment centers, pursuing National Cancer Institute designations and investing in value-based care. ChristianaCare, Wilmington, Delaware. IDN status: Advanced.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Improve Your Health, Meet in Person

PM360

The health-conscious among us pay special attention to actively managing our sleep, exercise, vitamins, etc. Biopharma should pay special attention to this. You’re the gatekeeper of all communication on your platform, and participants are unlikely to network with one another independently. The list goes on. Here’s why.

article thumbnail

The potential of AI in pharma R&D

Pharmaceutical Technology

Learn about how AI is helping companies right now, what to know about its benefits and challenges, and what’s needed to implement AI in biopharma research. They created neural networks that found multiple antibiotics from millions of candidates. According to Deloitte , 76% of biopharma companies invest in AI for clinical development.

Pharma 52